while female gender was the only significant positive predictor of longer RFS. Finally, the 5-fluorouracil-interferon combination was the most frequently used systemic therapy. Conclusions: Our analyses indicate that surgical approaches including metastasectomy as the first-line treatment in FLHCC correlated with better outcome. Multimodality approaches, including neoadjuvant and adjuvant therapies, prolonged patient survival.
chances of successful surgical resection [3, [5] [6] [7] [8] [9] . Several studies reported that prolonged survival associated with FLHCC was linked to greater feasibility of surgical resection, free surgical margins, and adequate lymph node dissection [10] ; absence of vascular invasion or lymph node metastasis, and normal liver functions [9, 11] . On the other hand, male sex, larger tumor size, and poor tumor differentiation have been found to correlate with poor prognosis in FLHCC [11] and are associated with a recurrence rate after resection as high as 50% [12, 13] . Because of the small number of cases reported, however, strong conclusions remain elusive, and, therefore, a lack of consensus on several aspects of FLHCC management remains a major challenge. For instance, while several reports have described the indolent nature of FLHCC and the superiority of surgical management in prolonging survival, few studies addressed the effect of neoadjuvant and adjuvant therapies on improving outcome. This is, in part, due to the conflicting data from studies using different regimens of chemotherapy in small patient cohorts.
We conducted a retrospective analysis of 94 consecutive patients with FLHCC treated at our institution. We examined their clinicopathologic features, treatment received, and predictors of clinical outcome. Our study comprises the largest single-institution series on FLHCC ever reported.
Patients and Methods

Study Design and Study Population
By searching the Tumor Registry Data of the University of Texas MD Anderson Cancer Center, we obtained a list of all patients with FLHCC who presented at our institution between 1992 and 2008. The protocol was approved by the Institutional Review Board of the MD Anderson Cancer Center. The diagnosis of FLHCC was confirmed for all patients by our pathologists. Structured data collection sheets were used and included demographic information, such as smoking, alcohol use, family history of cancer, medical history, and intake of hormones. A manual retrospective review of FLHCC patient records yielded clinical information such as disease stage, treatment approaches, chemotherapy regimens, and response to treatment.
The objective of this study was to collect all available clinical information regarding FLHCC patients, and analyze prognostic indicators and treatment outcomes. Each patient's disease stage was determined according to the American Joint Committee on Cancer (AJCC) TNM staging system of primary liver cancer [12] .
Statistical Methods
We used the Statistical Package for Social Sciences (SPSS, Chicago, Ill., USA) program for data management and statistical analysis. Survival curves were generated by the Kaplan-Meier method, and the statistical significance of the differences was determined according to Gehan's modification of the Wilcoxon signed-rank test. The Cox proportional hazard model and multivariate analyses were used to test prognostic factors associated with overall (OS) and recurrence-free survival (RFS) in all patients. Variables tested included age, sex, race, stage of the disease, vascular invasion, lymph node involvement, presence of extrahepatic metastases, treatment modalities (surgery vs. chemotherapy vs. local therapies), and sequence of therapy. Assumptions of the Cox regression analyses were verified and all reported p values were two sided.
Results
Patient Characteristics
The total number of HCC cases that presented to our center between the years 1992 and 2012 was 1,882. Of these, 1,786 patients had HCC and 96 patients had FLHCC (5.1%); 94 patients with pure FLHCC met the inclusion criteria, and 2 cases of FLHCC mixed with cholangiocarcinoma were excluded. The median age (range) of FLHCC patients was 23 years (range, 14-75), median OS was 57.2 months (95% confidence interval, CI, 36.4-77.9 months); the Kaplan-Meier survival curve is shown in figure 1 a. Forty-six of the 94 patients were females, and 7 were pregnant at the time of diagnosis. Most of the FLHCC cases were at an advanced stage at the time of initial diagnosis: AJCC stage III in 35 patients (38.2%) and AJCC stage IV in 39 patients (42.3%). Only 6 of 94 cases had evidence of cirrhosis (6.4%). Patients and disease characteristics are summarized in table 1 .
Factors Predictive of OS
We applied the univariate Cox regression analysis to our patient population to study the correlations between clinicopathologic factors and OS ( table 2 ). Non-White race, multinodularity, and carcinomatosis were the most significant predictors of shorter survival in our patients. Other factors that tended to have a positive effect on survival, but did not have significant p values, included female sex (p = 0.1), absence of cirrhosis (p = 0.1), absence of lymph node metastasis (p = 0.07), and absence of vascular invasion (p = 0.4). Furthermore, exposure to treatment ever was the most significant predictor of longer survival in these patients. Cox regression multivariate analysis showed a significant association between carcinomatosis and poor survival: hazard ratio (HR) = 3.5 (95% CI: 1.2-10.1, p = 0.01). Furthermore, White patients tended to have better survival compared with non-White patients: HR = 2.9 (95% CI: 0.9-9.7, p = 0.08). However, other factors included in table 2 showed no significant Table 3 includes chemotherapy regimens our patients received (53/94 patients), either in the neoadjuvant, adjuvant, or metastatic setting. Other systemic agents included sorafenib in 3 patients, and phase I trial agents in the form of proteasome inhibitor (n = 1), liposomal doxorubicin + hepatic arterial infusion of cisplatin (n = 1), pazopanib + trastuzumab (n = 1), pazopanib + vorinostat (n = 1), sunitinib + valproic acid (n = 3), bevacizumab + sorafenib (n = 1), and sirolimus + vorinostat (n = 2).
Notably, interferon (IFN) regimens were the most commonly used (47/53 patients), with best tumor response occurring with a regimen of 5-fluorouracil (5-FU) combined with IFN. Furthermore, a serum α-fetoprotein level above normal, although observed in only a few of the patients (n = 13), was a significant predictor of poor OS (p = 0.04).
We also studied the treatment modalities and their sequencing for patients for whom such records were available. Metastasectomy was done in 18 cases and was found to be significantly associated with longer OS: the median OS was 145 months for those who underwent metastasectomy versus 35 months for those who did not (p = 0.0001). A total of 49 patients underwent surgical treatment with curative intent, and 34 of these had lymphadenectomy, which did not have a significant impact on survival. Interestingly, patients who had frontline surgery followed by adjuvant therapies (n = 34) had the longest OS [110.5 months (95% CI, 66.1-154.9)], and those who underwent neoadjuvant therapy followed by surgery (n = 10) had a median OS of 60 months (95% CI, NA-123.9; p < 0.001; table 5 ; fig. 1 b) .
Factors Predictive of RFS
Of the 49 patients who underwent curative surgery, including 2 liver transplant cases, 5 had residual disease, and 41 patients had recurrent disease, indicating a recurrence rate of 83.7%. Median RFS was 13.9 months (95% CI, 8.8-18.9). Results of the Cox regression analysis of factors associated with RFS are summarized in table 5 . Notably, baseline staging had no significant impact on RFS, while female sex was the only significant positive predictor of longer RFS (HR = 3.1; 95% CI: 1.09-8.71, p = 0.3). Additionally, there was a trend toward longer RFS in patients who had single tumors and no vascular invasion.
Discussion
This study reports a single-institution experience with 94 FLHCC cases, which represented 5.1% of the total number of HCC cases referred to the institution during the period from 1992 to 2012. The availability of detailed medical records for our patients enabled a thorough analysis of prognostic indicators that correlated with OS and RFS after curative treatment approaches. Our results are consistent with and complimentary to previously reported observations regarding the clinicopathologic features of this rare disease and the advantages of surgical treatment approaches, including metastasectomy. Notably, patients also benefited from neoadjuvant and adjuvant multimodality therapy approaches. This is most likely related to disease down-staging among patients who presented initially at an advanced disease stage and eventually underwent surgical resection in addition to adjuvant local and systemic therapies. A recent study evaluated 30 cases of pure FLHCC [13] and reported a high incidence of metastasis especially to lymph nodes at presentation and upon relapse, which is consistent with our results ( table 1 ). The role of chemotherapy in the neoadjuvant, adjuvant, and advanced tumor setting in FLHCC has not been studied vigorously, and the few published reports show conflicting results for different combinations of systemic chemotherapy applied to small numbers of FLHCC patients [13] [14] [15] [16] . A recent multi-institution retrospective study of 95 FLHCC cases from three US centers reported a median OS of 6.7 years and indicated poor survival in females (median OS of 63.1 vs. 98.8 months in males, p = 0.03), advanced stage, unresectable disease, lymph node metastases, and macrovascular invasion [16] . While our study indicated a trend towards better outcome in fe- ( table 2 ) . However, our results of the favorable survival in females is consistent with a recent study that reported a 5-year survival rate of 62% in females versus 42% in males [13] . Another recent study based on data from the Surveillance, Epidemiology, and End Results Program reported a series of 191 FLHCC cases, the largest to date, with a 5-year OS rate of 34%, but no report of gender-specific rates, and revealed an interesting finding of two age-specific peaks for FLHCC, the first one in patients between 10 and 30 years and the second one in patients between 60 and 69 years, as compared to conventional HCC [17] . However, comparing results between studies of rare cancers has been challenging given the retrospective nature of collecting clinicopathologic data, in addition to the lack of detailed treatment history especially if collected from different institutions. Therefore, collaborative prospective studies in FLHCC are warranted to confirm these observations. Notably, our previous report on the results of a prospective phase II clinical trial of systemic continuous 5-FU and subcutaneous recombinant IFN α-2b for the treatment of HCC revealed that this regimen had promising activity in FLHCC cases [18] . The study included only 9 patients with FLHCC from a total of 43 HCC patients, but the 8 evaluable FLHCC patients had a median OS of 23 months: 1 patient had a complete response and 4 patients had a partial response. Our current analysis of a series of 27 patients treated with the same combination, in addition to 17 patients who received similar regimens ( table 3 ) , suggests potential benefits from the 5-FU-IFN chemotherapy combination in the neoadjuvant, adjuvant, and metastatic setting. This observation is interesting given the that one of the hallmark histopathologic features of FLHCC is the presence of laminated fibrous layers, interspersed between cancer cells, and the potential anti-fibrotic effects of IFN α-2b. However, prospective evaluation of this regimen is warranted.
Our study has several strengths, including the details on patient demographics, the large number of patients, which is the largest ever reported from a single institution, and the detailed multidisciplinary treatment history and follow-up. Limitations include being a retrospective analysis and the need to validate some of the results, such as gender variations in survival and treatment outcome.
In conclusion, progress in FLHCC management has been hampered by the lack of dedicated clinical trials, particularly with regard to systemic and local therapy approaches, in the neoadjuvant, adjuvant, and metastatic setting. Systemic and local therapies are particularly feasible for this patient population, given their lack of associated underlying chronic liver diseases that complicate HCC management. Such trials would be of great value in adding to our understanding of the natural history of FLHCC and improving the outcome of patients with this disease. One constraint on clinical trials of FLHCC is the small number of patients, which limits the significance of the results. This challenge highlights the importance of multicenter studies and international collaboration in this rare disease.
